By proceeding, you agree to our Terms of Use and Privacy Policy.
Greetings! Welcome to the 2nd Annual Oligonucleotides CMC & Analytical Development Summit, focused on accelerating scalability and regulatory approval through tightened QC of oligos for cost-efficient GMP manufacturing. With the oligonucleotides market projected to reach $2 billion by 2027 and over 250 clinical phase drug developments, we aim to expand the potential of oligonucleotides beyond rare diseases and use them to treat large patient populations for undruggable targets.In the past year, significant progress has been made in the field, with Switch Therapeutics advancing its first RNAi technology, Avidity turbocharging its antibody-oligo conjugate, and Ansa Biotech synthesizing the world's longest oligonucleotide. However, drug developers still face challenges in manufacturability and the lack of concrete regulatory protocols. That's why the 2nd annual Oligonucleotides CMC & Analytical Development Summit brings together 70+ industry leaders in CMC and analytical development to share their expertise and thought leadership.
Learn about the current research and developments for cost-efficient GMP manufacturing .
Gather in-depth knowledge on emerging analytical characterization for oligonucleotides, short oligomers, regulatory guidance & partnering, and more.
Take part in insightful sessions to scale up your oligonucleotide with long-term manufacturability in mind–from cost considerations to commercial scale.
Hear from top industry experts to capitalize on the next generation of oligonucleotides for non-rare disease indications and future growth opportunities.
Hanson Wade gives people the clarity to see where opportunity lies. We work in highly specialised fields to provide unmatched depth and quality of content. We work in sectors where quality of information is the difference between success and failure.
It was my first time there, and I was quite pleased with the quality of the talks.
Overall, I think it's a good conference, especially for people new to the area. It has been a good experience.
WuXi STA, a WuXi AppTec company, is a leading pharmaceutical development and manufacturing capability and technology platform company serving the life science industry, with four sites in China and two sites in the United States and one in Europe.
All trademarks, registered trademarks, product names, and company names or logos mentioned in or on this site are the property of their respective owners.
A great community. Legit content. The kind of emails you actually look forward to.